Shaperon Inc. (KOSDAQ:378800)

Market Cap	80.18B
Revenue (ttm)	29.51M
Net Income (ttm)	-13.58B
Shares Out	30.14M
EPS (ttm)	-472.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,051
Average Volume	453,682
Open	2,540.00
Previous Close	2,540.00
Day's Range	2,515.00 - 2,590.00
52-Week Range	1,694.00 - 5,900.00
Beta	-0.05
RSI	37.28
Earnings Date	Aug 14, 2025

About MorphoSys AG

Shaperon Inc., a clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics. It offers NuGel, a gel type atopic dermatitis drug candidate in Phase 2 clinical trials; and NuSepin, an IV injection form of HY209 in Phase 2 clinical trials for use in the treatment of systemic inflammatory response syndrome. The company also provides Oral HY209, an oral formulation of HY209 for use in the treatment of neuroinflammatory diseases; and H...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 49
• Stock Exchange: KOSDAQ
• Ticker Symbol: 378800

Financial Performance

In 2024, Shaperon's revenue was 17.70 million, a decrease of -91.77% compared to the previous year's 215.25 million. Losses were -14.90 billion, 20.2% more than in 2023.